# 2025-18000: FDA's Blueprint to Battle Invisible Heartburn Hell

2025-18000, Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-09-17 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-18000
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-18000
- Title: Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 44828
- Published: 2025-09-17
- Effective: unknown
- Comments close: 2025-11-17
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA's Blueprint to Battle Invisible Heartburn Hell

## Summary

The FDA just dropped a draft guide to help drug makers create better treatments for adults with symptomatic nonerosive gastroesophageal reflux disease (sGERD), a type of acid reflux without visible damage. This guide explains how to design clinical trials that prove new drugs work and are safe. Drug developers should check it out soon to speed up their research and bring relief to patients faster.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment." The draft guidance details FDA's recommendations on the clinical trials for drugs being developed for the treatment of symptomatic nonerosive gastroesophageal reflux disease (sGERD) in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-18000 on federalregister.gov](https://www.federalregister.gov/documents/2025/09/17/2025-18000/symptomatic-nonerosive-gastroesophageal-reflux-disease-developing-drugs-for-treatment-draft-guidance)
- [2025-18000 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-09-17/pdf/2025-18000.pdf)

## Related
- [Previous: 2025-17999, National Heart, Lung, and Blood Institute; Notice of Meeting](https://policyrisk.com/federal-register/2025-17999)
- [Next: 2025-18001, Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industr…](https://policyrisk.com/federal-register/2025-18001)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-18000 (as of 2026-06-08).
